Roche bets $1 billion on an anti-aging AI platform, without a single drug in the clinic

Roche bets $1 billion on an anti-aging AI platform, without a single drug in the clinic

In July 2025, Chugai Pharmaceutical (a Roche subsidiary) signed a deal with Gero, the AI biotech company founded by physicist Petr Fedichev. The agreement includes up to $250 million in milestone payments, with total potential value above $1 billion. Chugai gets exclusive rights to antibody drugs against targets identified by the platform.

What Chugai is buying. Gero has no molecules in clinical trials. What it has is an AI platform trained on 100+ million medical records that looks for causal pathways in age-related diseases, not correlations but mechanisms. Fedichev’s core idea is that the body gradually loses its ability to return to baseline after stress. Blood pressure swings more sharply, inflammatory markers fluctuate, metabolism becomes less stable. The platform separates the irreversible process itself, aging, from its reversible consequences, disease, and looks for intervention points.

In a recent preprint, the team described “phenotypic temperature,” a quantitative measure of that loss of order. The rate of damage accumulation does not depend on it, but mortality risk does directly. We covered this work in detail.

Why this deal is unusual. Big Pharma usually pays hundreds of millions for a portfolio of 2-3 candidates already in trials. Here, it is a platform with no molecules. Chugai is not buying a drug, but a way to find targets. If the first ones fail, access to the platform remains. In its press release, Chugai says this directly: the goal is “potentially aging itself.”

For context, Gero has a $20 million Series A, publications in Nature Communications, and a 2023 deal with Pfizer in fibrotic diseases. Chugai arrived with an order of magnitude more money and a different focus. And in July 2025, Brian Kennedy joined Gero’s board of directors, one of the world’s leading gerontologists.

The Chugai deal is one of the pharmaceutical industry’s biggest bets specifically on the mechanisms of aging, rather than on individual age-related diseases. The distinction is fundamental: instead of “we treat Alzheimer’s,” it is “we understand why the body stops coping.”